Non-Hodgkin Lymphoma
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
Conference Coverage
Atorvastatin cut anthracycline cardiac dysfunction in lymphoma
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
Conference Coverage
Care coordination, equity can eliminate disparities for nonwhite patients with DLBCL
The use of a nurse navigation program to facilitate care helped iron out racial disparities that could lead to poor outcomes.
Feature
ASCO to award $50,000 young investigator grant to study MCL
The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.
News
Group proposes new grading systems for CRS, neurotoxicity
A group of experts has proposed new consensus definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity related to...
News
Combo bests standard care in younger CLL patients
SAN DIEGO—In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger...
News
Fludarabine deemed important for CD30.CAR T-cell therapy
SAN DIEGO—Fludarabine is “very important” for lymphodepletion prior to CD30-directed chimeric antigen receptor (CAR) T-cell therapy, according to...
News
Mutation confers resistance to venetoclax in CLL
SAN DIEGO—A recurrent mutation in BCL2, the therapeutic target of venetoclax, appears to be a major contributor to drug resistance in patients...